Cargando…

Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients

BACKGROUND: In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to...

Descripción completa

Detalles Bibliográficos
Autores principales: Celejewska, Agata, Tukiendorf, Andrzej, Miszczyk, Leszek, Składowski, Krzysztof, Wydmański, Jerzy, Trela-Janus, Krystyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147185/
https://www.ncbi.nlm.nih.gov/pubmed/25298327
http://dx.doi.org/10.1186/s13048-014-0079-1
_version_ 1782332393565192192
author Celejewska, Agata
Tukiendorf, Andrzej
Miszczyk, Leszek
Składowski, Krzysztof
Wydmański, Jerzy
Trela-Janus, Krystyna
author_facet Celejewska, Agata
Tukiendorf, Andrzej
Miszczyk, Leszek
Składowski, Krzysztof
Wydmański, Jerzy
Trela-Janus, Krystyna
author_sort Celejewska, Agata
collection PubMed
description BACKGROUND: In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to establish survival in patients with a good health status and no more than three lesions. METHODS: Two parallel statistical methods in survival analysis were used: classical and Bayesian methods to verify statistical results. To display the predicted and posterior survivals, classification trees were built. RESULTS: From the initial set of prognostic factors, only four were established as statistically significant in multivariate regression. They were: survival to metastases to brain after epithelial ovarian cancer diagnosis, number of metastases at diagnosis, central nervous system radiotherapy prior to stereotactic radiotherapy, and interval to stereotactic radiotherapy after metastases diagnosis. CONCLUSIONS: When considering evidence-based standards of treatment of patients suffering from epithelial ovarian cancer brain metastases, the established clinical factors are suggested to be prognostic.
format Online
Article
Text
id pubmed-4147185
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41471852014-08-29 Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients Celejewska, Agata Tukiendorf, Andrzej Miszczyk, Leszek Składowski, Krzysztof Wydmański, Jerzy Trela-Janus, Krystyna J Ovarian Res Research BACKGROUND: In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to establish survival in patients with a good health status and no more than three lesions. METHODS: Two parallel statistical methods in survival analysis were used: classical and Bayesian methods to verify statistical results. To display the predicted and posterior survivals, classification trees were built. RESULTS: From the initial set of prognostic factors, only four were established as statistically significant in multivariate regression. They were: survival to metastases to brain after epithelial ovarian cancer diagnosis, number of metastases at diagnosis, central nervous system radiotherapy prior to stereotactic radiotherapy, and interval to stereotactic radiotherapy after metastases diagnosis. CONCLUSIONS: When considering evidence-based standards of treatment of patients suffering from epithelial ovarian cancer brain metastases, the established clinical factors are suggested to be prognostic. BioMed Central 2014-08-15 /pmc/articles/PMC4147185/ /pubmed/25298327 http://dx.doi.org/10.1186/s13048-014-0079-1 Text en © Celejewska et al.; licensee BioMed Central Ltd 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Celejewska, Agata
Tukiendorf, Andrzej
Miszczyk, Leszek
Składowski, Krzysztof
Wydmański, Jerzy
Trela-Janus, Krystyna
Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
title Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
title_full Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
title_fullStr Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
title_full_unstemmed Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
title_short Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
title_sort stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147185/
https://www.ncbi.nlm.nih.gov/pubmed/25298327
http://dx.doi.org/10.1186/s13048-014-0079-1
work_keys_str_mv AT celejewskaagata stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients
AT tukiendorfandrzej stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients
AT miszczykleszek stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients
AT składowskikrzysztof stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients
AT wydmanskijerzy stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients
AT trelajanuskrystyna stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients